Literature DB >> 28703825

Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

L Allott1, C Da Pieve1, J Meyers2, T Spinks1, D M Ciobota1, G Kramer-Marek1, G Smith1.   

Abstract

The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule DFO-HOPO (3) as a suitable chelator for 89Zr and a more stable alternative to DFO. The molecule showed good potential for the future development of a DFO-HOPO-based bifunctional chelator (BFC) for the radiolabelling of biomolecules with 89Zr. This work broadens the selection of available chelators for 89Zr in search of improved successors to DFO for clinical 89Zr-immuno-PET.

Entities:  

Year:  2017        PMID： 28703825      PMCID： PMC6055981          DOI： 10.1039/c7cc03572a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  16 in total

1.  Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands.

Authors:  D L White; P W Durbin; N Jeung; K N Raymond
Journal:  J Med Chem       Date:  1988-01       Impact factor: 7.446

Review 2.  89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals.

Authors:  Danielle J Vugts; Gerard W M Visser; Guus A M S van Dongen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 3.  PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors:  Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2012-09-19       Impact factor: 2.408

4.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Authors:  Maria J W D Vosjan; Lars R Perk; Gerard W M Visser; Marianne Budde; Paul Jurek; Garry E Kiefer; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

5.  89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Authors:  Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

6.  Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV).

Authors:  François Guérard; Yong-Sok Lee; Martin W Brechbiel
Journal:  Chemistry       Date:  2014-04-16       Impact factor: 5.236

7.  Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates.

Authors:  Chuangyan Zhai; Dominik Summer; Christine Rangger; Gerben M Franssen; Peter Laverman; Hubertus Haas; Milos Petrik; Roland Haubner; Clemens Decristoforo
Journal:  Mol Pharm       Date:  2015-05-19       Impact factor: 4.939

8.  Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).

Authors:  Melissa A Deri; Shashikanth Ponnala; Brian M Zeglis; Gabor Pohl; J J Dannenberg; Jason S Lewis; Lynn C Francesconi
Journal:  J Med Chem       Date:  2014-05-19       Impact factor: 7.446

Review 9.  Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Authors:  Yvonne W S Jauw; C Willemien Menke-van der Houven van Oordt; Otto S Hoekstra; N Harry Hendrikse; Danielle J Vugts; Josée M Zijlstra; Marc C Huisman; Guus A M S van Dongen
Journal:  Front Pharmacol       Date:  2016-05-24       Impact factor: 5.810

Review 10.  (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.

Authors:  Gabriel Fischer; Uwe Seibold; Ralf Schirrmacher; Björn Wängler; Carmen Wängler
Journal:  Molecules       Date:  2013-06-03       Impact factor: 4.411
View more
  8 in total

Review 1.  Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies.

Authors:  Minh Thanh La; Van Hieu Tran; Hee-Kwon Kim
Journal:  Nucl Med Mol Imaging       Date:  2019-01-29

2.  Polyazamacrocycle Ligands Facilitate 89Zr Radiochemistry and Yield 89Zr Complexes with Remarkable Stability.

Authors:  Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal:  Inorg Chem       Date:  2020-11-10       Impact factor: 5.165

3.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

4.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

5.  A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.

Authors:  Elaheh Khozeimeh Sarbisheh; Akam K Salih; Shvan J Raheem; Jason S Lewis; Eric W Price
Journal:  Inorg Chem       Date:  2020-07-28       Impact factor: 5.165

Review 6.  Recent Advances in Zirconium-89 Chelator Development.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Thaddeus J Wadas
Journal:  Molecules       Date:  2018-03-12       Impact factor: 4.411

7.  Ultra-selective ligand-driven separation of strategic actinides.

Authors:  Gauthier J-P Deblonde; Abel Ricano; Rebecca J Abergel
Journal:  Nat Commun       Date:  2019-06-04       Impact factor: 14.919

8.  Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET.

Authors:  René Raavé; Gerwin Sandker; Pierre Adumeau; Christian Borch Jacobsen; Floriane Mangin; Michel Meyer; Mathieu Moreau; Claire Bernhard; Laurène Da Costa; Adrien Dubois; Victor Goncalves; Magnus Gustafsson; Mark Rijpkema; Otto Boerman; Jean-Claude Chambron; Sandra Heskamp; Franck Denat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-03       Impact factor: 9.236
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.